Home Newsfeeds Keybanc Maintains Overweight on Target, Lowers Price Target to $180

Keybanc Maintains Overweight on Target, Lowers Price Target to $180

Keybanc analyst Bradley Thomas maintains Target (NYSE:TGT) with a Overweight and lowers the price target from $200 to $180.

byBenzinga Newsdesk

November 17, 2022

1 minute read

Keybanc analyst Bradley Thomas maintains Target (NYSE:TGT) with a Overweight and lowers the price target from $200 to $180.

News

BorgWarner To Deliver Electric Variable Cam Timing Technology To Global OEM

By Benzinga Newsdesk

June 23, 10:01 AM

Technology to be used in select four-cylinder engineseVCT reduces emissions and significantly improves fuel economy and performanceSOP slated for December 2024AUBURN HILLS, Mich., June 23, 2023 /PRNewswire/ -- BorgWarner

BWA

News

What’s Going On With UnitedHealth Group (UNH) Shares

By Henry Khederian

July 19, 12:36 PM

UnitedHealth Group Inc (NYSE: UNH) shares are trading higher by 1.35% to $506.89 Wednesday afternoon. Shares of healthcare stocks are trading higher in sympathy with Elevance Health, which reported better-than-expected second-quarter financial results and raised guidance.

UNH

Ethereum Creator Vitalik Buterin Raises Eyebrows Over WorldCoin’s Proof-of-Personhood: ‘Iris Scans Might Reveal More Information’

By Mehab Qureshi

July 24, 6:12 AM

Vitalik Buterin, co-founder of Ethereum (CRYPTO: ETH), on Monday, expressed his concerns about Sam Altman

ETH

News

On Dec 30, 2022, Aquestive Therapeutics Received Notice Of Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq

By Happy Mohamed

January 3, 2:44 PM

On December 30, 2022, Aquestive Therapeutics, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule

AQST

Keybanc Maintains Overweight on Target, Lowers Price Target to $180

Related Posts

BorgWarner To Deliver Electric Variable Cam Timing Technology To Global OEM

What’s Going On With UnitedHealth Group (UNH) Shares

Ethereum Creator Vitalik Buterin Raises Eyebrows Over WorldCoin’s Proof-of-Personhood: ‘Iris Scans Might Reveal More Information’

On Dec 30, 2022, Aquestive Therapeutics Received Notice Of Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq